Tislelizumab plus sitravatinib as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after surgical resection: Preliminary analysis of a multi-center, non-randomized, open-label phase 2 study

被引：0

作者：

Wang, Jiabei

Peng, Tao

Liu, Chang

Zhang, Ling

Zhu, Guangzhi

Zhang, Xiaogang

Wang, Xiaoqian

Liu, Lianxin

机构：

[1] USTC, Affiliated Hosp 1, Hefei, Peoples R China

[2] Guangxi Med Univ, Affiliated Hosp 1, Nanning, Peoples R China

[3] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Peoples R China

[4] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China

[5] Univ Sci & Technol China, Div Life Sci & Med, Affiliated Hosp 1, Hefei, Peoples R China

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e16239

引用

页数：1